These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Antibodies to m-type phospholipase A2 receptor in children with idiopathic membranous nephropathy. Kumar V; Ramachandran R; Kumar A; Nada R; Suri D; Gupta A; Kohli HS; Gupta KL; Jha V Nephrology (Carlton); 2015 Aug; 20(8):572-5. PubMed ID: 26194981 [TBL] [Abstract][Full Text] [Related]
28. Duodenal Schwannoma as a Rare Association With Membranous Nephropathy: A Case Report. Zhang Z; Gong T; Rennke HG; Hayashi R Am J Kidney Dis; 2019 Feb; 73(2):278-280. PubMed ID: 30454884 [TBL] [Abstract][Full Text] [Related]
29. Rituximab In The Treatment Of Refractory Idiopathic Membranous Nephropathy In Pakistani Population. Anjum N; Nabi Z; Alam MA J Ayub Med Coll Abbottabad; 2019; 31(2):265-268. PubMed ID: 31094128 [TBL] [Abstract][Full Text] [Related]
30. How to Choose the Right Treatment for Membranous Nephropathy. Peritore L; Labbozzetta V; Maressa V; Casuscelli C; Conti G; Gembillo G; Santoro D Medicina (Kaunas); 2023 Nov; 59(11):. PubMed ID: 38004046 [TBL] [Abstract][Full Text] [Related]
31. Anti-PLA2R Antibodies as a Prognostic Factor in PLA2R-Related Membranous Nephropathy. Timmermans SA; Abdul Hamid MA; Cohen Tervaert JW; Damoiseaux JG; van Paassen P; Am J Nephrol; 2015; 42(1):70-7. PubMed ID: 26344651 [TBL] [Abstract][Full Text] [Related]
32. Membranous nephropathy: Mechanistic insights and therapeutic perspectives. Hua MR; Zhao YL; Yang JZ; Zou L; Zhao YY; Li X Int Immunopharmacol; 2023 Jul; 120():110317. PubMed ID: 37207447 [TBL] [Abstract][Full Text] [Related]
33. Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy. van den Brand JAJG; Ruggenenti P; Chianca A; Hofstra JM; Perna A; Ruggiero B; Wetzels JFM; Remuzzi G J Am Soc Nephrol; 2017 Sep; 28(9):2729-2737. PubMed ID: 28487395 [TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of rituximab therapy for membranous nephropathy: a meta-analysis. Zhang J; Bian L; Ma FZ; Jia Y; Lin P Eur Rev Med Pharmacol Sci; 2018 Nov; 22(22):8021-8029. PubMed ID: 30536351 [TBL] [Abstract][Full Text] [Related]
35. Low-dose rituximab is poorly effective in patients with primary membranous nephropathy. Moroni G; Depetri F; Del Vecchio L; Gallelli B; Raffiotta F; Giglio E; Brunini F; D'Amico M; Longhi S; Radice A; Messa P; Sinico RA Nephrol Dial Transplant; 2017 Oct; 32(10):1691-1696. PubMed ID: 27387472 [TBL] [Abstract][Full Text] [Related]
36. Treatment of membranous nephropathy with crescent nephritis by rituximab: A case report. Zhang F; Yang Y; Chen Y; Chen Y; Yin W; Liang Y; Luo X Medicine (Baltimore); 2022 Sep; 101(37):e30663. PubMed ID: 36123923 [TBL] [Abstract][Full Text] [Related]
37. Membranous nephropathy with crescents: a series of 19 cases. Rodriguez EF; Nasr SH; Larsen CP; Sethi S; Fidler ME; Cornell LD Am J Kidney Dis; 2014 Jul; 64(1):66-73. PubMed ID: 24709471 [TBL] [Abstract][Full Text] [Related]
38. Bortezomib therapy for nephrotic syndrome due to idiopathic membranous nephropathy. Hartono C; Chung M; Kuo SF; Seshan SV; Muthukumar T J Nephrol; 2014 Feb; 27(1):103-6. PubMed ID: 24430762 [TBL] [Abstract][Full Text] [Related]
39. The Beneficial Role Of Anti-Phospholipase A2 Receptor Auto-Antibodies And Rituximab In The Management Of Recurrent Primary Membranous Nephropathy After Kidney Transplantation. Anjum N; Nabi Z J Ayub Med Coll Abbottabad; 2021; 33(2):315-318. PubMed ID: 34137554 [TBL] [Abstract][Full Text] [Related]
40. Treatment of Membranous Nephropathy in Patients With THSD7A Antibodies Using Immunoadsorption. Weinmann-Menke J; Holtz S; Sollinger D; Dörken M; Boedecker S; Schamberger B; Pfister F; Amann K; Lutz J Am J Kidney Dis; 2019 Dec; 74(6):849-852. PubMed ID: 31451329 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]